STOCK TITAN

LianBio - LIAN STOCK NEWS

Welcome to our dedicated news page for LianBio (Ticker: LIAN), a resource for investors and traders seeking the latest updates and insights on LianBio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LianBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LianBio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
none
LianBio

Nasdaq:LIAN

LIAN Rankings

LIAN Stock Data

34.47M
25.38M
5.91%
78.99%
0.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Princeton

About LIAN

lianbio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in china and major asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. lianbio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.